Floatz logo

PR 104

Lung Cancer

Proacta, IncorporatedSmall moleculePhase 2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

PR 104 is also rated in:

cancer of unknown primary siteDormant
CCC
Indicative ·
48 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
45 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →